Heparin is an anticoagulant used to decrease the clotting ability of blood and help to prevent harmful clots from forming in blood vessels. It is sometimes referred as a blood thinner, although it does not actually thin the blood. Heparin does not dissolve already formed blood clots, but it can prevent the clots from becoming larger and causing more serious problems. Pharmaceutical-grade heparin is derived from animal tissue. Heparin is commonly used in the treatment of coronary heart disease, pulmonary embolism, deep vein thrombosis, and atrial fibrillation, and in the prevention of thrombosis during extracorporeal membrane oxygenation and cardiopulmonary bypass.
Market Dynamics
Rising cases of conditions such as coronary heart disease, pulmonary embolism, and deep vein thrombosis is one of the major factors for increased demand of heparin drugs in the market. Myocardial infarction (MI) is one of the major complications of coronary heart disease. According to the American Heart Association 2018 report, coronary heart disease is the leading cause (43.8%) of deaths due to cardiovascular disease in the U.S., followed by stroke (16.8%). As per the Centres for Disease Control and Prevention (CDC) 2015 report, deep vein thrombosis affects nearly 900,000 individuals in the U.S. each year.
Despite major applications in chronic conditions, heparin is poorly absorbed by the intestine, therefore it must be given intravenously or subcutaneously. Moreover, the drug creates a significant risk of excessive bleeding due to anticlotting effect. Heparin also induce conditions such as thrombocytopenia (reduced number of circulating platelets) and hypersensitivity reactions. These factors can hamper the heparin market, during the forecast period.
Key features of the study:
- This report provides in-depth analysis of the heparin market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global heparin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global heparin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for heparin market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Heparin Market, By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- Global Heparin Market, By Dosage Form:
- Global Heparin Market, By Region:
- North America
- By Country:
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Africa
- By Country:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Company Profiles
- Anselm Pharmaceuticals*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Baxter International Inc.
- Braun Melsungen AG
- Bristol-Myers Squibb Co.
- Reddy’s Laboratories Ltd.
- Fresenius SE & Co. KGaA
- Leap Labchem Co.
- LEO Pharma A/S
- Pfizer, Inc.
- Sanofi S.A.
- Syntex S.A.
- Teva Pharmaceutical Industries Ltd.
- United Biotech (P) Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
